Miltenyi Biotec

www.miltenyibiotec.com

We’re committed to helping researchers and clinicians make a greater impact on science and health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

news image

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

Cell and Gene Therapy, Industrial Impact

GI CELL ENTERS AGREEMENT WITH OPTIEUM BIOTECHNOLOGIES

GI CELL | December 13, 2022

news image

GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targets generated through Optieum Biotechnologies’ Eumbody System™. GI CELL will carry out feasibility studies and be responsible for further development and commercialization of the CAR-NK cell products if the company exercises an option. ...

Read More

Cell and Gene Therapy

CIMEIO THERAPEUTICS ANNOUNCES ISSUANCE OF KEY PATENT COVERING CELL THERAPY PLATFORM

Cimeio | November 29, 2022

news image

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D.,...

Read More

Cell and Gene Therapy, MedTech

PEAR THERAPEUTICS AND SPERO HEALTH TO COLLABORATE AND EXPAND ACCESS TO PDTS

Pear Therapeutics | January 09, 2023

news image

Pear Therapeutics, Inc., the leader in commercializing and developing software-based medicines known as prescription digital therapeutics (PDTs), announced the expansion of its collaboration with Spero Health, an integrated healthcare services organization. Spero Health, which has adopted reSET® and reSET-O® at 14 locations in Kentucky, plans to expand access to eligible patients at its remaining 99 locations in Kentucky, Indiana, Ohio, Tennessee, Virginia, and West Virgin...

Read More
news image

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

news image

Cell and Gene Therapy, Industrial Impact

GI CELL ENTERS AGREEMENT WITH OPTIEUM BIOTECHNOLOGIES

GI CELL | December 13, 2022

GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targets generated through Optieum Biotechnologies’ Eumbody System™. GI CELL will carry out feasibility studies and be responsible for further development and commercialization of the CAR-NK cell products if the company exercises an option. ...

Read More
news image

Cell and Gene Therapy

CIMEIO THERAPEUTICS ANNOUNCES ISSUANCE OF KEY PATENT COVERING CELL THERAPY PLATFORM

Cimeio | November 29, 2022

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D.,...

Read More
news image

Cell and Gene Therapy, MedTech

PEAR THERAPEUTICS AND SPERO HEALTH TO COLLABORATE AND EXPAND ACCESS TO PDTS

Pear Therapeutics | January 09, 2023

Pear Therapeutics, Inc., the leader in commercializing and developing software-based medicines known as prescription digital therapeutics (PDTs), announced the expansion of its collaboration with Spero Health, an integrated healthcare services organization. Spero Health, which has adopted reSET® and reSET-O® at 14 locations in Kentucky, plans to expand access to eligible patients at its remaining 99 locations in Kentucky, Indiana, Ohio, Tennessee, Virginia, and West Virgin...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us